CNTX
Context Therapeutics Inc

5,230
Mkt Cap
$264.61M
Volume
636,188.00
52W High
$3.62
52W Low
$0.49
PE Ratio
-10.29
CNTX Fundamentals
Price
$2.88
Prev Close
$2.99
Open
$2.99
50D MA
$2.34
Beta
0.95
Avg. Volume
1.21M
EPS (Annual)
-$0.4575
P/B
3.62
Rev/Employee
$0.00
$32.87
Loading...
Loading...
News
all
press releases
Context Therapeutics (NASDAQ:CNTX) Rating Increased to Hold at Wall Street Zen
Wall Street Zen raised Context Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday...
MarketBeat·1d ago
News Placeholder
More News
News Placeholder
Context Therapeutics Outlines Post-ADC T-Cell Engager Strategy, Teases Q2 Claudin 6 Data
Context Therapeutics (NASDAQ:CNTX) is focused on developing T-cell engager (TCE) therapies for solid tumors, with an emphasis on addressing resistance that can emerge after antibody-drug conjugate...
MarketBeat·8d ago
News Placeholder
Context Therapeutics (CNTX) to Release Earnings on Thursday
Context Therapeutics (NASDAQ:CNTX) will be releasing its Q4 2025 earnings before the market opens on Thursday, March 19. (View Earnings Report at...
MarketBeat·10d ago
News Placeholder
Context Therapeutics CEO Teases Q2 Claudin 6 Data, Nectin-4 Clinic Entry at TD Cowen Conference
Context Therapeutics (NASDAQ:CNTX) CEO Martin Lehr outlined the company's strategy and upcoming clinical milestones at the 46th Annual TD Cowen Healthcare Conference, positioning the biotechnology...
MarketBeat·14d ago
News Placeholder
Context Therapeutics Inc. (NASDAQ:CNTX) Receives Average Recommendation of "Moderate Buy" from Brokerages
Shares of Context Therapeutics Inc. (NASDAQ:CNTX - Get Free Report) have been assigned an average rating of "Moderate Buy" from the nine research firms that are covering the company, MarketBeat...
MarketBeat·19d ago
News Placeholder
Wall Street Zen Downgrades Context Therapeutics (NASDAQ:CNTX) to Sell
Wall Street Zen downgraded Context Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday...
MarketBeat·22d ago
News Placeholder
Research Analysts Offer Predictions for CNTX FY2025 Earnings
Context Therapeutics Inc. (NASDAQ:CNTX - Free Report) - Analysts at Lifesci Capital issued their FY2025 earnings per share (EPS) estimates for shares of Context Therapeutics in a note issued to...
MarketBeat·25d ago
News Placeholder
Lifesci Capital Upgrades Context Therapeutics (NASDAQ:CNTX) to "Strong-Buy"
Lifesci Capital raised Context Therapeutics to a "strong-buy" rating in a research report on Monday...
MarketBeat·26d ago
News Placeholder
Context Therapeutics (NASDAQ:CNTX) Upgraded to Hold at Wall Street Zen
Wall Street Zen upgraded shares of Context Therapeutics from a "sell" rating to a "hold" rating in a report on Monday...
MarketBeat·1mo ago
News Placeholder
Context Therapeutics (NASDAQ:CNTX) Lowered to Sell Rating by Wall Street Zen
Wall Street Zen lowered Context Therapeutics from a "hold" rating to a "sell" rating in a research report on Sunday...
MarketBeat·1mo ago
<
1
2
...
>

Latest CNTX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.